Evolution of the Average Target: RH

Evolution of the Target Price: RH

Changes in Analyst Recommendations: RH

7d573f215857ecb2433af46aca.eSaWcS3WfZrejPK7PJ6McW-l-db0dCXAkkWDTAZ4Tr0.KUHPOmayNf6a6IONTdz7QB6Wz6WmIW_w3n3FIjEVe9UvFK5Aep8p8JDkuw~4450452c6941df2a5e91c4118f41028a
08/07 Goldman Sachs Upgrades RH to Neutral From Sell, Lifts Price Target to $155 From $86 MT
09/06 RH Q1 Unlikely to Show Business Inflection, UBS Says MT
09/06 UBS Adjusts Price Target on RH to $155 From $160, Maintains Neutral Rating MT
01/04 Guggenheim Lowers Price Target on RH to $200 From $275, Keeps Buy Rating MT
01/04 RH Facing Near-Term Challenges From Execution, Supply Chain Issues, Morgan Stanley Says MT
01/04 Morgan Stanley Lowers Price Target on RH to $240 From $275, Keeps Overweight Rating MT
20/12 JPMorgan Cuts Price Target on RH to $225 From $275, Maintains Overweight Rating MT
12/12 Stifel Downgrades RH to Hold From Buy, Adjusts Price Target to $165 From $320 MT
02/25/02 William Blair Downgrades RH to Market Perform From Outperform MT
12/25/12 Telsey Advisory Downgrades RH to Market Perform From Outperform, Adjusts Pt to $220 From $255 MT
25/25/25 RH Shares Fall After Goldman Sachs Downgrade MT
24/25/24 Goldman Sachs Downgrades RH to Sell From Neutral, Adjusts Price Target to $179 From $199 MT
05/25/05 UBS Adjusts RH Price Target to $215 From $235, Maintains Neutral Rating MT
14/25/14 BofA Securities Adjusts Price Target on RH to $172 From $144 MT
07/25/07 RH Cash Flow, Demand Guidance Eases Tariff Concerns, Wedbush Says MT
03/25/03 RH Earnings Troubles Exacerbated by Trump Tariffs, Wedbush Says; Shares Down Pre-Bell MT
03/25/03 Wedbush Adjusts RH Price Target to $250 From $350, Maintains Outperform Rating MT
03/25/03 UBS Adjusts Price Target on RH to $235 From $250, Keeps Neutral Rating MT
27/25/27 RH Could See Solid Sales, Soft Margins for Fiscal Q4, Wedbush Says MT
26/25/26 BofA Securities Cuts RH Price Target to $410 From $510, Maintains Buy Rating MT
26/25/26 Wedbush Cuts Price Target on RH to $350 From $500, Keeps Outperform Rating MT
21/25/21 UBS Adjusts Price Target on RH to $250 From $440, Keeps Neutral Rating MT
30/25/30 Goldman Sachs Upgrades RH to Neutral From Sell, Raises Price Target to $374 From $261 MT
13/25/13 Morgan Stanley Upgrades RH to Overweight From Equalweight, Raises Price Target to $530 From $435 MT
08/25/08 Barclays Upgrades RH to Overweight From Equalweight, Raises Price Target to $515 From $383 MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
-10.93%
-4.58%
+15.23%
+32.92%
+45.64%
+11.36%
+25.04%
+13.46%
-3.69%
+39.7%
Average +16.42%
Weighted average by Cap. +3.53%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
190.26USD
Average target price
169.47USD
Spread / Average Target
-10.93%
High Price Target
270.00USD
Spread / Highest target
+41.91%
Low Price Target
90.00USD
Spread / Lowest Target
-52.70%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Goldman Sachs
UBS
Guggenheim
Morgan Stanley
JPMorgan Chase
Stifel Nicolaus
William Blair & Co.
Telsey Advisory Group
BofA Securities
Wedbush
Barclays
Baird
Jefferies & Co.
BNP Paribas Exane
TD Cowen
Wells Fargo Securities
Loop Capital
Citigroup
Cowen
Gordon Haskett
J.P. Morgan Chase
Trader
Investor
Global
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
190.26USD
Average target price
169.47USD
Spread / Average Target
-10.93%

Quarterly revenue - Rate of surprise